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PreviewsIt now appears that genome-wide
approaches using high-throughput
sequencing technologies may provide
this sorely needed perspective. In this
issue of Cancer Cell, Riggi et al. (2014)
demonstrate that EWS/FLI1 target genes
can be parsed into two groups: (1) genes
that are upregulated by EWS/FLI1 primar-
ily through interacting with GGAA re-
peats present in satellite DNA within the
genome and (2) genes that are downregu-
lated by EWS/FLI1, whose regulatory re-
gions contain canonical ETS-binding sites
normally bound by ETS factors and that,
in Ewing sarcoma, are displaced by the
fusion. While some of these data echo
previous findings from other investigative
groups, the power of this current study
is in its broad scope. By assessing EWS/
FLI1 occupancy at target gene regulatory
sites along with co-factor occupancy
and histone modification, broad trends
are coming to light that can serve as a
logical framework describing the EWS/
FLI1 target gene network.
Particularly intriguing is the further vali-
dation that EWS/FLI1 can use GGAA re-
peats as genomic response elements.
This observation, first made by Gangwal
et al. (2008), prompted a fundamental
mechanistic insight into the relative sus-
ceptibility of developing Ewing sarcoma.
They posited that perhaps the very low596 Cancer Cell 26, November 10, 2014 ª20incidence of Ewing sarcoma in the African
population is due to differences in GGAA-
containing satellite DNA polymorphisms.
The further development by Riggi et al.
(2014) that, in binding GGAA repeats,
EWS/FLI1 can then imbue them with
enhancer-like qualities confirms at a mo-
lecular level another long-held belief that
EWS/FLI1 is more than the sum of its
parts. Functioning as a true chimera,
EWS/FLI1 can do what neither normal
EWS nor FLI1 can do.
While Riggi et al. (2014) provide an
initial view into the broad EWS/FLI1 tar-
get gene landscape, further refinement
can be anticipated. It seems likely that
not all genes that are transcriptionally
modulated by EWS/FLI1 promote onco-
genesis in Ewing sarcoma. Distinguishing
the pathophysiologically significant sub-
set from the incidental targets will be a
challenge. In this regard, fusion of large
data sets generated by this and other par-
allel studies could help to further refine
EWS/FLI1 target gene network models
(Wang et al., 2012).
Functionally inhibiting the EWS/FLI1
oncogenic program in a therapeutically
meaningful way still seems like a daunting
proposition. Simultaneous inhibition of
the correct combination of target genes
will likely be necessary to bring down
this network. The hope that studies such14 Elsevier Inc.as Riggi et al. (2014) inspire is that, in
describing the system, it can now be stra-
tegically navigated. With the advent of
such tools, the era of generating therapies
to combat Ewing sarcoma based on
educated guess and empiric intuition will
hopefully draw to a close.REFERENCES
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Plexiform neurofibromas are one of themost common tumors encountered in individuals with the neurofibro-
matosis type I (NF1) cancer predisposition syndrome. In this issue ofCancer Cell, Chen and colleagues define
the cell of origin for murine Nf1 plexiform neurofibroma and leverage this finding to develop a platform for
preclinical drug evaluation.Neurofibromatosis type I (NF1) is one of
the most common cancer predisposition
syndromes, affecting 1 in 2,500 individ-
uals worldwide (Lin and Gutmann, 2013).Among the diverse number of benign
and malignant neoplasms observed in
this condition, peripheral nerve sheath
tumors (neurofibromas) are found innearly all adults with NF1. One subtype
of neurofibroma, the plexiform neurofi-
broma, is a particularly challenging tumor
to manage. These extensive, highly
embryonic postnatal
adolescent adult
NCSC SCP iSC SC
Wnt1
P0(A)
DHH
Krox20 Krox20
PLP
Figure 1. NF1-Associated Plexiform Neurofibromas
(A–E) Plexiform neurofibromas can be located in many regions of the body, including the orbit surrounding the eyeball and optic nerve (A), neck (B), paraspinal
regions involving spinal nerve roots (C, inset), subcutaneous space under the skin (D), and extremities (E), such as the lower leg and foot. Asterisks denote the
tumors.
(F) Numerous genetically engineeredmousemodels have been generated using different cell type-specific promoters and ages of somaticNf1 gene inactivation.
(G) The clinical heterogeneity of plexiform neurofibromas in people with NF1may partly reflect the specific cell type with loss of neurofibromin function, including
the neural crest stem cell (NCSC), Schwann cell precursor (SCP), immature Schwann cell (iSC), andmature Schwann cell (SC) as well as the age at which somatic
Nf1 gene inactivation occurs. Moreover, nonneoplasticNf1+/ stromal cells (macrophages, endothelial cells, andmast cells) likely also contribute to differences in
plexiform neurofibroma clinical behavior. The lines bracket the developmental window during which Nf1 gene loss in appropriate Schwann cell lineage cells re-
sults in plexiform neurofibroma formation. PNF, plexiform neurofibroma.
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Previewsvascular tumors typically involve multiple
nerves or large segments of a nerve
root, making complete surgical removal
nearly impossible. In addition, they often
affect adjacent structures in the body,
leading to tissue compression (narrowed
trachea or nerve impingement), bone
erosion, or fatty replacement of muscle.
Moreover, cytotoxic chemotherapy for
plexiform neurofibromas has had modest
effectiveness, and the use of radiation is
limited by the risk of secondary malignant
transformation.These benign nerve sheath tumors can
arise anywhere within the body, including
the eye socket (orbit; Figure 1A), neck
(Figure 1B), spinal nerve roots (Figure 1C),
subcutaneous tissue (Figure 1D), and
extremities (Figure 1E). While histological-
ly similar, their clinical behavior is influ-
enced by the age of the patient and
location of the tumor. First, the majority
of plexiform neurofibromas grow most
rapidly during the first decade of life.
Second, while subcutaneous and orbital
plexiform neurofibromas rarely trans-Cancer Cell 26, Nform into malignant peripheral nerve
sheath tumors, there is a 10%–13% life-
time risk of malignant transformation for
plexiform neurofibromas involving other
body regions. Third, treatment with a
biologically-targeted therapy (Imatinib)
revealed greater responses in tumors of
the neck and pelvis relative to those in
other locations (Robertson et al., 2012).
Together, these clinical observations
raise the intriguing possibility that plexi-
form neurofibromas arising in different
areas are biologically distinct entitiesovember 10, 2014 ª2014 Elsevier Inc. 597
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Previewsand that the development of effective
treatments will necessitate a deeper un-
derstanding of the molecular and cellular
differences that underlie this innate
heterogeneity.
As such, several different genetically
engineered mouse models (GEMMs) of
NF1-associated plexiform neurofibroma
have been generated (Figure 1F). Rele-
vant to the human condition, Nf1 GEMMs
have emerged as critical experimental
platforms to define the molecular and
cellular pathogenesis of plexiform neuro-
fibroma formation and growth. In this re-
gard, these murine tumor models have
been employed to demonstrate that plex-
iform neurofibromas can arise from some
cell types (Schwann cell precursors,
immature Schwann cells, and mature
Schwann cells; Le et al., 2011; Zhu et al.,
2002; Wu et al., 2008; Mayes et al.,
2011), but not others (neural crest stem
cells; Joseph et al., 2008). Similarly, both
the penetrance and location of plexiform
neurofibroma development is impacted
by the age at which somatic Nf1 gene
inactivation occurs, with rare tumors
arising following acquiredNf1 loss in adult
mice (Le et al., 2011).
In this issue of Cancer Cell, Chen et al.
(2014) determined that Nf1 murine spinal
plexiform neurofibromas arise from a
small population of PLP+ Schwann cell
precursors within the embryonic nerve
root. Using embryonic dorsal root
ganglion/nerve root neurosphere cells
(DNSCs), they demonstrated that Nf1-
deficient DNSCs generate plexiform neu-
rofibromas following injection into the
sciatic nerves of naive immunocompro-
mised mice. The development of tumors
in mice without a germline Nf1 gene mu-
tation or intact immune system further
adds to the controversy over the abso-
lute requirement for a supportive Nf1+/
microenvironment in plexiform neurofi-
broma pathogenesis. In this regard,
dependence on bone marrow-derived
cells (mast cells and macrophages) and
endothelial cells in the Nf1+/ tumor
microenvironment has been demon-
strated in some models (Joseph et al.,
2008; Le et al., 2011; Yang et al., 2008;
Zhu et al., 2002), but not in others (Mayes
et al., 2011; Wu et al., 2008; Chen et al.,
2014). It is also possible that the ability to
form tumors in wild-type mice reflects
some degree of local injury at the site
of the sciatic nerve injection sufficient598 Cancer Cell 26, November 10, 2014 ª20to provide a supportive microenviron-
ment for tumorigenesis (Ribeiro et al.,
2013).
Next, they employed inducible PLP-
CreER mice to define the population of
DNSCs most responsible for tumor for-
mation, revealing that PLP+ tumorigenic
cells express the GAP43 Schwann cell
precursor protein. In keeping with previ-
ous studies using Krox20-Cre (Zhu et al.,
2002; Yang et al., 2008) or DHH-Cre
(Mayes et al., 2011; Wu et al., 2008)
mouse strains to generate plexiform
neurofibromas, they found that Krox20+
and DHH+ cells were contained within
the PLP+ DNSC population. Based on
these fate mapping experiments, the
authors conclude that PLP+, GAP43+
embryonic Schwann cell precursors
represent the cellular origin for spinal
plexiform neurofibromas.
Finally, because neurofibromin, the
protein encoded by NF1, negatively regu-
lates RAS/RAF/MEK activity relevant to
murine Nf1 GEMM plexiform neurofi-
broma growth, Chen et al. (2014) utilized
their Nf1-deficient DNSC sciatic nerve
transplant model to perform proof-of-
concept studies using the selective MEK
inhibitor PD0325901. They found that
suppression of MEK activity reduced
plexiform neurofibroma growth in vivo,
further establishing this preclinical model
as a tractable platform for future thera-
peutic drug discovery and evaluation.
These encouraging results provide sup-
port for two ongoing humanMEK inhibitor
clinical studies on NF1-associated plexi-
form neurofibroma (www.clinicaltrials.
gov; NCT01362803, NCT02096471).
Together with other Nf1 GEMM work,
this study reveals that specific cell
types during particular developmental
windows are exquisitely vulnerable to
the tumorigenic effects of somatic Nf1
gene inactivation. Similar to NF1-associ-
ated plexiform neurofibromas, not all cell
types in the glial lineage are capable
of generating NF1-associated low-grade
brain tumors (optic gliomas). Somatic
Nf1 gene loss must occur in neural stem
cells originating within one specific
germinal zone (third ventricle) during
embryogenesis in order for mice to
develop optic gliomas (Lee et al., 2012).
The requirement for somatic loss of Nf1
gene expression in a particular cell of
origin during a restricted period of life
may partly explain why not all people14 Elsevier Inc.with NF1 develop particular tumors, why
these tumors arise in specific locations,
and why they may exhibit different growth
properties or responses to biologically
targeted therapies.
Beyond the important insights into
pathogenesis that these experimental
findings provide, they additionally offer
exciting opportunities to develop Nf1
GEMMs that more accurately match spe-
cific subtypes of NF1-related tumors. It is
important to recognize that the Nf1
GEMM plexiform neurofibroma model re-
ported by Chen et al. (2014) most closely
resembles the human paraspinal subtype
(Figure 1C). As such, the growth control
pathways deregulated in this subtype
(e.g., MEK) and the relative contributions
from the local microenvironment (e.g.,
athymic mice) may be most germane to
this tumor subgroup. The creation of addi-
tional GEMMs that model other types of
plexiform neurofibromas observed in peo-
ple with NF1 will likely entail defining the
cells of origin and vulnerable windows for
each subtype using different regulatable
Cre driver lines to enable somatic Nf1
loss in distinct cell types during defined
periods of development (Figure 1G).
The availability of subtype-specific
plexiform neurofibroma mouse strains
would facilitate unbiased discovery ef-
forts aimed at determining how these tu-
mors are molecularly distinct from each
other. In this manner, the unique biol-
ogies of these different subgroups and
their respective mechanisms of growth
regulation might be discerned. This
knowledge coupled with the ability to
establish xenograft models as executed
by Chen et al. (2014) opens the door to
the identification of drug therapies that
might be particularly efficacious for each
one of the varieties of plexiform neurofi-
broma. Furthermore, these future studies
may lead to a greater appreciation of the
factors that drive plexiform neurofibroma
growth relevant to individual patient risk
assessment. Continued progress in this
area has the potential to allow for the
development of prognostic strategies
and treatments personalized to a given
patient’s tumor.ACKNOWLEDGMENTS
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Autophagy is an important cellular homeostasis pathway, but its role in cancer remains to be fully elucidated.
In this issue of Cancer Cell, Hall and colleagues describe a TRPM3-dependent autophagy pathway that is
selectively important for clear cell renal cell carcinoma and can be effectively inhibited.Autophagy is a highly conserved homeo-
static mechanism for the degradation
and recycling of bulk cytoplasm, organ-
elles, and long-lived proteins through the
lysosomal machinery. Given its role in
cellular homeostasis, it is not surprising
that autophagy has been found to be
deregulated in many human diseases,
including cancer (Schneider and Cuervo,
2014). However, how autophagy contrib-
utes to cancer ontogenesis and progres-
sion has turned out to be more complex
than expected. Overall, the emerging
concept is that autophagy has both
positive and negative effects, depending
on the tumor stage. While functional auto-
phagy prevents tumor initiation, its pro-
survival effect may allow transformed
cells to resist against adverse conditions.
Consistently, several studies demon-
strated that different autophagy-related
genes play a central role in tumorigenesis
by controlling tumor growth and/or tumor
suppression (Guo et al., 2013; Takahashi
et al., 2007). Further, more recent evi-
dence highlighted the existence of addi-tional roles besides autophagy regulation
for autophagy-related factors. Indeed,
the key pro-autophagic molecule Beclin
1 may also act in vacuolar protein sorting
and the degradation of specific growth
factor receptors (Funderburk et al., 2010).
More recently, a role for Beclin 1-medi-
ated autophagy in the regulation of cancer
cell growth induced by the epidermal
growth factor receptor has also been
demonstrated (Wei et al., 2013). Such
multiple roles for autophagy regulators
may reflect the need for an integrated
regulation of metabolic homeostasis.
One hypothesis about the impact of
autophagy on cancer is that autophagy-
deficient cells accumulate malfunctioning
proteins and organelles, leading to reac-
tive oxygen species production, DNA
damage, chromosomal instability, and
activation of oncogenes. Another possi-
bility is that autophagy plays a negative
role in the control of cell proliferation.
Indeed, mice with monoallelic deletion of
Becn1 or Bif1 display a hyperproliferative
phenotype (Qu et al., 2003; Takahashiet al., 2007). On the other hand, in a
cancer that develops in the absence
of any recognizable autophagy defects,
autophagy acts as an effective pro-
survival process for cancer cells to
sustain metabolic distress, react to pro-
death stimuli, and circumvent nutrient
deficiency. Along this line, autophagy
represents a metabolic ‘‘addiction’’ for a
successful cancer cell (Guo et al., 2013).
As a consequence of this duality for
cancer-related autophagy, the develop-
ment of cancer therapies targeting auto-
phagy is still very preliminary. Indeed,
although the inconsiderate inhibition of
autophagy may be beneficial for the
treatment of well-established tumors, it is
potentially dangerous to the patients’
health. Therefore, generally disturbing
the autophagy machinery or the auto-
phagosome/autophagolysosome func-
tion should be avoided. In fact, it has
beendescribed that autophagy deficiency
is responsible for tumorigenesis as well as
defects in a plethora of other physiological
processes (Schneider and Cuervo, 2014).ovember 10, 2014 ª2014 Elsevier Inc. 599
